Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

20191,693 citationsJournal Articlebronze Open Access

Authors

Noopur Raje · Massachusetts General Hospital

Jesús G. Berdeja · Sarah Cannon

Yi Lin · Dana-Farber Cancer Institute

David S. Siegel · Hackensack University Medical Center

Sundar Jagannath · Mount Sinai Medical Center

Deepu Madduri · Mount Sinai Medical Center

Michaela Liedtke

Abstract

We report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma. Antitumor activity was documented. (Funded by Bluebird Bio and Celgene; CRB-401 ClinicalTrials.gov number, NCT02658929.).

Topics & Keywords

CAR-T cell therapy research Integrated Circuits and Semiconductor Failure Analysis Nanowire Synthesis and Applications

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 380, Issue 18, pp. 1726-1737

DOI: 10.1056/nejmoa1817226

Field-Weighted Citation Impact: 94.99